This article from the Lancashire Telegraph (don't you read it?), praising the achievements of the East Lancashire Hospitals NHS Trust (which beat its target for clinical research by almost 200 per cent: during 2010/11 there were 2,905 patients involved in research – nearly three times the target of 1,000) gives further evidence of the success of the Clinical Research Networks established by the NIHR.
This is a topic we cover in our current market analysis - some of which I reproduce below - for further info, email finlay[.]macdougall[@]ncri.org.uk:
The National Cancer Research Network has more than quadrupled the number of patients entering clinical trials in England between 2001 and 2011: “Within 3 years, as the networks were established, recruitment of patients to studies doubled from 10000 to 20000 cancer patients per year. Recruitment has continued to increase year on year, supported initially by underspend that had accrued from earlier years in the life of the NCRN, and more recently from additional resources invested via the NIHR comprehensive networks. Provisional data for the year 2009/2010 suggest that over 40000 patients enrolled into portfolio studies in England, with over 45000 across the whole of the UK.”(a)
The Scottish Cancer Research Network has more than doubled patient recruitment to Scottish clinical research studies in cancer.(b)
In terms of lead-time on trials, the networks are able to help combat bureaucracy issues such as site feasibility, recruitment and patient engagement.(c)
(a) Cameron D, et al. (2010) Four-fold increase in recruitment of cancer patients to NCRN portfolio studies
between 2001 and 2010: a tale of investment bringing returns. NCRI Cancer Conference, 7-10 November 2010
(c) Clinical Trials in the UK: A World Leading Clinical Research Environment in the Areas of Oncology, Medicines for Children and Early Stage Research – a publication of the Department for UK Trade and Investment [March 2010] with a foreword by the President of the ABPI